转移性前列腺癌锁骨上淋巴结转移的立体定向放疗结局
本研究分析了419例淋巴结转移性前列腺癌患者中16例(3.8%)经PET发现左侧锁骨上淋巴结(SCLN)转移并接受SBRT的结局。SBRT耐受良好,无≥2级毒性,5年局部无复发生存率为90.9%,但远处进展常见,提示需密切监测并强化全身治疗。
要点
- SCLN转移多见于初诊后多年,中位PSA低且多数为单发或少数淋巴结受累。
- SBRT后无≥2级毒性,5年局部无复发生存率达90.9%。
- 去势敏感患者5年前列腺癌特异性生存率100%,mCRPC患者为58.3%。
核心结论
- SCLN的SBRT耐受良好且无显著毒性,局部控制持久满意。
- SCLN转移常预示进一步转移进展,患者需密切监测并可能受益于全身治疗强化。
研究设计与样本
- 回顾性分析2017至2024年间419例淋巴结转移性前列腺癌患者,其中16例(3.8%)经前列腺特异性PET发现SCLN受累。
- 分析生存、复发模式和毒性。
主要发现
- 初诊时中位PSA为6.7 ng/mL(范围2.1-315),50%患者Gleason评分8-10。
- 从初诊至SCLN转移的平均时间为10.4年,中位PSA为2.0 ng/mL,中位受累SCLN数为1.5个(范围1-10)。
- 最常用分割方案为35 Gy分5次每日照射(44%),81%患者接受同期激素治疗。
- 未报告≥2级毒性;5年局部无复发生存率为90.9%。
- 平均远处无进展生存期为16.7个月(95%CI:7.9-25.5),平均前列腺癌特异性生存期和总生存期分别为4.6年(95%CI:3.6-5.6)和4.0年(95%CI:2.8-5.1)。
关键数值与推荐
- 去势敏感疾病患者5年前列腺癌特异性生存率为100%,mCRPC患者为58.3%。
临床怎么用
- SCLN寡转移患者可考虑SBRT以获良好局部控制和低毒性。
- SCLN转移后应密切监测远处进展,并考虑强化全身治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVES: Metastasis directed therapy (MDT) with stereotactic body radiotherapy (SBRT) has demonstrated clinical benefit among select oligometastatic prostate cancer (PCa) patients. The outcomes of SBRT to the left supraclavicular lymph nodes (SCLNs) are examined. MATERIALS/METHODS: Between 2017 and 2024, 16 (3.8%) of 419 patients with PCa metastatic to lymph nodes were found by prostate-specific PET to have SCLN involvement. Survival, relapse patterns, and toxicity are analyzed. RESULTS: At initial PCa diagnosis, median PSA was 6.7 ng/mL (range 2.1-315) with 50% of patients having Gleason score of 8-10. Mean time from initial diagnosis to SCLN metastasis was 10.4 years with median PSA of 2.0 ng/mL and median number of involved SCLNs of 1.5 (range 1-10). The most common fractionation scheme was 35 Gy in 5 fractions daily (44%) with 81% of patients receiving concurrent hormonal therapy. No grade ≥ 2 toxicities were reported. Local relapse-free survival at 5 years was 90.9%. Mean distant progression-free survival was 16.7 months (95% CI: 7.9-25.5). Mean prostate cancer-specific survival (PCSS) and overall survival were 4.6 years (95% CI: 3.6-5.6) and 4.0 years (95% CI: 2.8-5.1), respectively. Patients with castration-sensitive disease had 100% 5-year PCSS, and 58.3% for those with mCRPC. CONCLUSION: SBRT to SCLNs was well tolerated with no significant toxicity. Durable local control was satisfactory. The presence of SCLN metastases is frequently a harbinger of additional metastatic progression which suggests that patients require close monitoring and could benefit from the addition or intensification of systemic therapy.
引用
- Frias AL, Stish BJ, Phillips RM, et al. Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancer. Clin Transl Radiat Oncol. 2026. PMID: 42028344. doi:10.1016/j.ctro.2026.101168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。